NDAORALSOLUTIONPriority Review
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
SELZENTRY (maraviroc) by GSK is chemokine co-receptor 5 antagonists [moa]. Approved for ccr5 co-receptor antagonist [epc]. First approved in 2016.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Selzentry (maraviroc) is an oral small-molecule CCR5 co-receptor antagonist approved in 2016 for treatment of HIV-1 infection. It works by blocking the chemokine receptor 5 (CCR5) on the surface of CD4+ T cells, preventing HIV entry into cells. The drug is indicated for CCR5-tropic HIV-1 infected patients and represents a distinct mechanism within antiretroviral therapy.
$0.009BPart D
PeakStable
Product is in peak commercial phase with stable Medicare Part D utilization, indicating mature market penetration and a focused, stable commercial team supporting a niche but established therapy.
Mechanism of Action
Chemokine Co-receptor 5 Antagonists
Pharmacologic Class:
CCR5 Co-receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Started Sep 2022
120 enrolled
Stroke
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Started Jun 2020
60 enrolled
COVID-19
Maraviroc to Augment Rehabilitation Outcomes After Stroke
Started Aug 2019
2 enrolled
Stroke
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Started Jun 2017
47 enrolled
HIV Infections
Maraviroc Efficacy for Hepatitis C
Started Jun 2017
10 enrolled
Hepatitis CHuman Immunodeficiency Virus
Worked on SELZENTRY at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.